Diversified Trust Co Makes New Investment in Cumberland Pharmaceuticals Inc. $CPIX

Diversified Trust Co bought a new position in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 700,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $5,481,000.

Several other large investors also recently made changes to their positions in CPIX. Dimensional Fund Advisors LP increased its stake in shares of Cumberland Pharmaceuticals by 1.5% in the first quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company’s stock valued at $898,000 after buying an additional 4,081 shares in the last quarter. Lantern Wealth Advisors LLC bought a new position in shares of Cumberland Pharmaceuticals in the third quarter valued at about $106,000. Arrowstreet Capital Limited Partnership acquired a new position in Cumberland Pharmaceuticals during the 1st quarter worth about $66,000. Bank of New York Mellon Corp acquired a new position in Cumberland Pharmaceuticals during the 2nd quarter worth about $379,000. Finally, BlackRock Inc. acquired a new position in Cumberland Pharmaceuticals during the 2nd quarter worth about $412,000. Institutional investors own 15.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Cumberland Pharmaceuticals presently has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Price Performance

CPIX stock opened at $5.88 on Friday. The company has a 50 day moving average price of $6.64 and a 200 day moving average price of $5.57. Cumberland Pharmaceuticals Inc. has a fifty-two week low of $1.85 and a fifty-two week high of $9.28. The stock has a market capitalization of $88.08 million, a PE ratio of 1.31 and a beta of 0.16.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company based in Nashville, Tennessee. Founded in 1999, the company develops, acquires and commercializes branded prescription medicines, with a focus on products used in hospital and other acute-care settings as well as treatments for chronic conditions. Its marketed products include Acetadote, an intravenous treatment for acetaminophen overdose; Caldolor, an intravenous ibuprofen product used to treat pain and fever; and Kristalose, a prescription treatment for constipation.